Please use this identifier to cite or link to this item:
Full metadata record
DC FieldValueLanguage
dc.contributor.authorMyrianthefs, P.en
dc.contributor.authorMarkantonis, S. L.en
dc.contributor.authorVlachos, K.en
dc.contributor.authorAnagnostaki, M.en
dc.contributor.authorBoutzouka, E.en
dc.contributor.authorPanidis, D.en
dc.contributor.authorBaltopoulos, G.en
dc.rightsDefault Licence-
dc.subjectAcetamides/*blood/*cerebrospinal fluiden
dc.subjectAnti-Infective Agents/*blood/*cerebrospinal fluiden
dc.subjectArea Under Curveen
dc.subjectBacterial Infections/*blood/cerebrospinal fluid/drug therapyen
dc.subjectBrain Diseases/complications/*surgeryen
dc.subjectChromatography, High Pressure Liquiden
dc.subjectCritical Illnessen
dc.subjectGram-Positive Bacteria/drug effectsen
dc.subjectMicrobial Sensitivity Testsen
dc.subjectMiddle Ageden
dc.subjectNeurosurgical Proceduresen
dc.subjectOxazolidinones/*blood/*cerebrospinal fluiden
dc.subjectProspective Studiesen
dc.titleSerum and cerebrospinal fluid concentrations of linezolid in neurosurgical patientsen
heal.type.enJournal articleen
heal.type.elΆρθρο Περιοδικούel
heal.recordProviderΠανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικήςel
heal.abstractLinezolid is a new antimicrobial agent effective against drug-resistant gram-positive pathogens commonly responsible for central nervous system (CNS) infections in neurosurgical patients hospitalized in intensive care units. In order to study the penetration of this antimicrobial into the cerebrospinal fluid (CSF) of such patients, the disposition of linezolid in serum and CSF was studied in 14 neurosurgical patients given linezolid at 600 mg twice daily (1-h intravenous infusion) for the treatment of CNS infections caused by gram-positive pathogens or for prophylactic chemotherapy. Serum and CSF linezolid steady-state concentrations were analyzed by high-pressure liquid chromatography, and the concentration-time profiles obtained were analyzed to estimate pharmacokinetic parameters. The mean +/- standard deviation (SD) linezolid maximum and minimum measured concentrations were 18.6 +/- 9.6 microg/ml and 5.6 +/- 5.0 microg/ml, respectively, in serum and 10.8 +/- 5.7 microg/ml and 6.1 +/- 4.2 microg/ml, respectively, in CSF. The mean +/- SD areas under the concentration-time curves (AUCs) were 128.7 +/- 83.9 microg x h/ml for serum and 101.6 +/- 59.6 microg x h/ml for CSF, with a mean penetration ratio for the AUC for CSF to the AUC for serum of 0.66. The mean elimination half-life of linezolid in CSF was longer than that in serum (19.1 +/- 19.0 h and 6.5 +/- 3.6 h, respectively). The serum and CSF linezolid concentrations exceeded the pharmacodynamic breakpoint of 4 microg/ml for susceptible target pathogens for the entire dosing interval in the majority of patients. These findings suggest that linezolid may achieve adequate concentrations in the CSF of patients requiring antibiotics for the management or prophylaxis of CNS infections caused by gram-positive pathogens.en
heal.journalNameAntimicrob Agents Chemotheren
Appears in Collections:Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά)

Files in This Item:
File Description SizeFormat 
Myrianthefs-2006-Serum and cerebrospi.pdf184.18 kBAdobe PDFView/Open

This item is licensed under a Creative Commons License Creative Commons